{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-040532","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.162738+00:00","generated_at":"2026-06-04T06:35:42.950356+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Arrivent Biopharma reports FY 2023 net loss of $69.3M; cash runway into 2026 after $201M IPO","bullets":["R&D expenses $64.9M in 2023, up from $30.4M in 2022 on increased furmonertinib trial spending.","Net loss $69.3M vs $37.0M in prior year; cash & marketable securities $150.4M at Dec 31, 2023.","Completed $201M IPO in Jan 2024; management expects operations funded into 2026.","FDA granted Breakthrough Therapy Designation for furmonertinib in NSCLC with EGFR exon 20 ins.","Proof-of-concept data for furmonertinib in PACC mutations expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-040532","json":"https://secwatch.observer/filing/0001104659-24-040532.json","markdown":"https://secwatch.observer/filing/0001104659-24-040532.md","text":"https://secwatch.observer/filing/0001104659-24-040532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924040532/0001104659-24-040532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924040532/tm249692d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:35:42.950356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd9d8493610b13698a77a4360cd1838d59f0c022","claim":"ArriVent BioPharma, Inc. reported the full year ended December 31, 2023 results: net income Net loss was $69.3 million.","evidence_excerpt":"ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924040532/0001104659-24-040532-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $69.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}